Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 OcellO, Merus Enter Research Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

OcellO, Merus Enter Research Pact

To provide in vitro research services for Merus’ Phase I MCLA-158 Biclonics program

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

OcellO B.V., a Contract Research Organization offering 3D cell based assay services for drug discovery, has entered an agreement to provide in vitro research services to Merus N.V., a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, for Merus’ MCLA-158 Biclonics program.

OcellO will provide €1 million of in vitro research services to Merus over a period of two years. OcellO will also utilize its 3D immune-oncology co-culture screening technology to support other undisclosed Merus Biclonics discovery programs.

Merus is developing MCLA-158 in Phase I in patients with solid tumors with an initial focus on metastatic colorectal cancer. MCLA-158 is designed to bind to cancer stem cells expressing leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5) and epidermal growth factor receptors (EGFR).

“With this new commitment, Merus looks forward to extending its long-standing productive relationship with the OcellO team,” said Mark Throsby, chief scientific officer of Merus.

“This significant service agreement between OcellO and Merus enables OcellO to further invest in its technology platform – particularly for immune-oncology drug discovery – to meet the needs of Merus and other companies in the immune-oncology space,” said Leo Price, chief executive officer of OcellO.
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters